Kaleido

The Montreal Cognitive Assessment (MoCA) is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA empowers healthcare professionals and researchers to detect cognitive impairment related to conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Lewy Body Dementia, VCI/Stroke, frontotemporal dementia, brain metastasis, ALS, sleep behavior disorder, brain tumors, multiple sclerosis, head trauma, depression, schizophrenia, heart failure, substance abuse, HIV, COVID, and more. MoCA is regularly used by nurses, primary care and specialty physicians, occupational therapists, speech-language pathologists, psychologists, researchers, and other clinicians. It quickly and accurately assesses short-term memory, visuospatial abilities, executive functions, attention, concentration and working memory, language, and orientation to time and place.

Specialty and rare diseases have undefined patient populations, with individuals who are undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their manifestations, as well as treatment journeys that are not well understood. IPM.ai is an Insights-as-a-Service (IaaS) company that empowers the world’s leading life sciences brands to better understand and improve the lives of patients through the development, clinical study, and commercialization of therapeutic interventions. Maximize commercialization efforts by forecasting market size, competitive landscape, and potential ROI. Uncover ideal patients who are undiagnosed and/or misdiagnosed who may be appropriate for disease interception and therapeutic intervention. Statistically model the number of disease cases present in a particular patient population at a given time. Identify physicians who diagnose and treat ideal patients and influence other health care providers.